uniQure (NASDAQ:QURE) Upgraded at Cantor Fitzgerald

uniQure (NASDAQ:QURE) was upgraded by Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research note issued to investors on Wednesday. The brokerage presently has a $61.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 28.11% from the company’s current price.

A number of other brokerages also recently commented on QURE. Barclays restated a “positive” rating on shares of uniQure in a research note on Wednesday. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $35.00 in a research note on Monday, March 9th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research note on Monday, April 20th. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Finally, Wolfe Research initiated coverage on shares of uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.17.

uniQure Stock Performance

Shares of QURE stock traded up $20.62 on Wednesday, hitting $47.61. 11,513,314 shares of the stock traded hands, compared to its average volume of 2,641,930. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The company has a market capitalization of $3.00 billion, a PE ratio of -13.53 and a beta of 0.98. uniQure has a 1-year low of $8.73 and a 1-year high of $71.50. The company’s fifty day moving average is $22.93 and its 200 day moving average is $21.75.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, equities research analysts predict that uniQure will post -3.64 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, Director Leonard E. Post sold 1,993 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the sale, the director directly owned 35,494 shares of the company’s stock, valued at $960,467.64. This represents a 5.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David D. Meek sold 1,993 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the sale, the director directly owned 39,747 shares of the company’s stock, valued at approximately $1,075,553.82. This represents a 4.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 85,817 shares of company stock valued at $2,232,383 over the last 90 days. 4.65% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently bought and sold shares of QURE. State Street Corp lifted its stake in uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC lifted its stake in uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new stake in uniQure in the 4th quarter worth about $33,062,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure announced plans to submit a BLA for AMT-130, saying the FDA agreed the company’s three-year data could serve as the primary basis for an accelerated approval filing. Article Title
• Positive Sentiment: Public reports indicate the FDA’s recent dialogue was more favorable than earlier guidance, which had suggested uniQure might need a larger randomized trial; that shift materially improves the near-term regulatory path. Article Title
• Neutral Sentiment: Trading volume jumped and the stock attracted unusual call option activity, suggesting traders are positioning aggressively around the FDA news rather than on operating results alone.
• Neutral Sentiment: Recent insider and institutional trading data show mixed longer-term sentiment, but these flows are secondary to today’s regulatory catalyst.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.